RELAXaHEAD for Headache Patients (Phase III)
Part of paid clinical trials in New York, New York.
- Sponsor
- NYU Langone Health
- Study ID
- NCT06077838
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 16 Years - 80 Years
- Healthy Volunteers
- Not accepted
Interventions
- RELAXaHEAD Smartphone App Version 1 — BEHAVIORALRELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts.
- RELAXaHEAD Smartphone App Version 2 — BEHAVIORALRELAXaHEAD is a smartphone application that allows users to track headache frequency and severity, sleep, medication, medication side effects, and menstrual cycle, and create personal notes daily. The RELAXaHEAD app has an option for users to view their data reports and charts. This version also contains audio materials.
Study Details
This study is a fully powered, remote randomized control trial to evaluate RELAXaHEAD in people with migraine.
Key Dates
- Start date
- Nov 8, 2023
- Status verified
- Oct 2025
- Primary completion
- Aug 31, 2028
- Completion
- Aug 31, 2028
Study Design
- Enrollment
- 356 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: RELAX Group 1Participants will receive access to the RELAXaHEAD app version 1 which contains certain features for migraine self-management with written materials.
- Active Comparator: RELAX Group 2Participants will receive access to the RELAXaHEAD app version 2 which contains certain features for migraine self-management with written and audio materials.
Primary Outcome Measure
Change from Baseline in Modified Monthly Migraine Disability Assessment Scale (mMIDAS) Score [ Time Frame: Baseline, Week 6 ]
Central Contacts
- Mia T Minen, MD212-263-7744
- Erin Waire929-455-5591
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| NYU Langone Health | New York | New York | 10016 | - |
Find similar trials in New York, NY
By condition
By specialty
By research site
Related Studies
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)PHASE3 · Recruiting · AbbVie · Huntsville, Alabama
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)PHASE3 · Enrolling By Invitation · AbbVie · Huntsville, Alabama
- Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric SubjectsPHASE3 · Recruiting · Pfizer · Fort Smith, Arkansas
- A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic MigrainePHASE3 · Recruiting · H. Lundbeck A/S · New Haven, Connecticut